Literature DB >> 23588314

CYP3A5 genotype, but not CYP3A4*1b, CYP3A4*22, or hematocrit, predicts tacrolimus dose requirements in Brazilian renal transplant patients.

A B Santoro, C J Struchiner, C R Felipe, H Tedesco-Silva, J O Medina-Pestana, G Suarez-Kurtz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23588314     DOI： 10.1038/clpt.2013.68

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  14 in total

Review 1.  Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients.

Authors:  Alessio Provenzani; Andrew Santeusanio; Erin Mathis; Monica Notarbartolo; Manuela Labbozzetta; Paola Poma; Ambra Provenzani; Carlo Polidori; Giovanni Vizzini; Piera Polidori; Natale D'Alessandro
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

2.  Multigene predictors of tacrolimus exposure in kidney transplant recipients.

Authors:  Rebecca A Pulk; David S Schladt; William S Oetting; Weihua Guan; Ajay K Israni; Arthur J Matas; Rory P Remmel; Pamala A Jacobson
Journal:  Pharmacogenomics       Date:  2015-06-12       Impact factor: 2.533

3.  Effect of ABCB1 diplotype on tacrolimus disposition in renal recipients depends on CYP3A5 and CYP3A4 genotype.

Authors:  T Vanhove; P Annaert; D Lambrechts; D R J Kuypers
Journal:  Pharmacogenomics J       Date:  2016-07-05       Impact factor: 3.550

4.  Evaluation of tacrolimus-related CYP3A5 genotyping in China: Results from the First External Quality Assessment Exercise.

Authors:  Guigao Lin; Xiao Zhang; Kuo Zhang; Yanxi Han; Liming Tan; Jinming Li
Journal:  J Clin Lab Anal       Date:  2018-04-30       Impact factor: 2.352

5.  Role of pharmacogenomics in dialysis and transplantation.

Authors:  Kelly Birdwell
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-11       Impact factor: 2.894

6.  The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients.

Authors:  H de Jonge; L Elens; H de Loor; R H van Schaik; D R J Kuypers
Journal:  Pharmacogenomics J       Date:  2014-10-07       Impact factor: 3.550

Review 7.  The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.

Authors:  Dennis A Hesselink; Rachida Bouamar; Laure Elens; Ron H N van Schaik; Teun van Gelder
Journal:  Clin Pharmacokinet       Date:  2014-02       Impact factor: 6.447

Review 8.  Pharmacogenetics and drug-induced nephrotoxicity in renal transplant recipients.

Authors:  Sepideh Zununi Vahed; Mohammadreza Ardalan; Nasser Samadi; Yadollah Omidi
Journal:  Bioimpacts       Date:  2015-02-21

9.  Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation.

Authors:  D J A R Moes; J J Swen; J den Hartigh; T van der Straaten; J J Homan van der Heide; J S Sanders; F J Bemelman; J W de Fijter; H J Guchelaar
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-02-12

10.  Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients.

Authors:  D J A R Moes; S A S van der Bent; J J Swen; T van der Straaten; A Inderson; E Olofsen; H W Verspaget; H J Guchelaar; J den Hartigh; B van Hoek
Journal:  Eur J Clin Pharmacol       Date:  2015-10-31       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.